Bis-indolylmethane Adjuvants Potentiate Antibiotic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic development is hindered by the high cost and low investment returns, leading to a lack of new antibiotics and strategies to combat antibiotic resistance.
Innovation Solution
Development of antimicrobial agents and compounds that potentiate existing antimicrobial agents, specifically pharmaceutical compositions containing compounds with Formula A or B, which enhance the activity of antibiotics and overcome resistance mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new antibiotics are developed through traditional methods, then antibiotic activity is improved, but development cost and time increase significantly
Solution Approach 1:
The patent applies preliminary action by developing adjuvant compounds that can be combined with existing antibiotics. Instead of developing entirely new antibiotics from scratch, the invention prepares auxiliary agents in advance that enhance the effectiveness of already-established antibiotics, thereby reducing development time while maintaining or improving antibiotic activity.
Solution Approach 2:
The patent employs composite materials by creating pharmaceutical compositions that combine adjuvant compounds with existing antibiotics. These composite formulations leverage the synergistic effects between the adjuvant and the antibiotic, achieving enhanced antimicrobial activity without requiring the lengthy development process of creating a completely new antibiotic molecule.
2Productivity
If investment in antibiotic development increases, then new antibiotics are developed, but investment returns decrease
Solution Approach 1:
The patent applies universality by creating adjuvant compounds that can work with multiple different antibiotic classes. A single adjuvant compound can enhance the activity of various antibiotics against different resistant pathogens, allowing pharmaceutical companies to develop one versatile agent that serves multiple therapeutic purposes, thereby improving productivity while reducing the need for extensive separate development programs.
Solution Approach 2:
The patent employs parameter changes by modifying the pharmacological parameters of existing antibiotics through combination with adjuvants. Rather than changing the fundamental antibiotic molecule, the invention alters the effective concentration, spectrum of activity, or resistance-breaking capability by combining with auxiliary compounds, thus achieving development output with reduced investment risk.
3Reliability
If adjuvant compounds are developed to overcome resistance, then antibiotic effectiveness is improved, but the number of clinically approved adjuvants remains limited
Solution Approach 1:
The patent applies segmentation by dividing the resistance problem into specific mechanisms and developing targeted adjuvant compounds for each. Rather than seeking a single universal solution, the invention creates multiple specialized adjuvants that address different resistance mechanisms (e.g., efflux pumps, beta-lactamases, membrane permeability), thereby increasing the overall number of approved adjuvants through focused development programs.
Solution Approach 2:
The patent employs intermediary compounds that mediate between the antibiotic and the resistant pathogen. These adjuvant compounds act as intermediaries that either inhibit resistance mechanisms or enhance antibiotic penetration, providing a bridge that restores antibiotic effectiveness without requiring direct modification of the antibiotic molecule itself.
Data Source
AI summary
A pharmaceutical composition is described herein, including an antimicrobial agent and a compound having Formula A, or Formula B. Methods of using the pharmaceutical compositions to treat microbial infection are also described.